Alkermes plc. Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
Alkermes plc. (ALKS) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $1.83 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-15.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2019-02-15
- Alkermes plc. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2012-03-31 was $1.21M.
- Alkermes plc. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2011-12-31 was $0.00.
- Alkermes plc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2016 was $1.83M, a 93.60% decline from fiscal 2015.
- Alkermes plc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2015 was $28.58M, a 11.71% decline from fiscal 2014.
- Alkermes plc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2014 was $32.37M.
- Alkermes plc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2013 was $8.87M, a 104.54% increase from fiscal 2012.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 3 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 6 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 9 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month |
|---|---|---|---|---|
| 2016-12-31 | $1.83M 10-K · filed 2019-02-15 | |||
| 2015-12-31 | $28.58M 10-K · filed 2018-02-16 | |||
| 2014-12-31 | $32.37M 10-K · filed 2017-02-17 | |||
| 2013-12-31 | $11.39M 10-K · filed 2016-02-25 | |||
| 2013-03-31 | $8.87M 10-K · filed 2015-02-24 | |||
| 2012-03-31 | $1.21M derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | $1.21M derived: sum of 2 quarters · filed 2014-02-27 | $4.33M 10-KT · filed 2014-02-27 | |
| 2011-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-02 | $3.13M 10-Q · filed 2012-02-02 | ||
| 2011-09-30 | $3.13M 10-Q · filed 2011-11-03 | |||
| 2010-03-31 | $246.00K 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |